aTyr Pharma (LIFE) Rating Lowered to Hold at Zacks Investment Research

Zacks Investment Research downgraded shares of aTyr Pharma (NASDAQ:LIFE) from a buy rating to a hold rating in a report issued on Wednesday.

According to Zacks, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. “

Separately, ValuEngine cut shares of aTyr Pharma from a sell rating to a strong sell rating in a research note on Friday, December 1st. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the stock. aTyr Pharma has a consensus rating of Hold and a consensus price target of $4.81.

Shares of aTyr Pharma (LIFE) traded down $0.20 during mid-day trading on Wednesday, hitting $3.95. 10,577 shares of the company were exchanged, compared to its average volume of 38,320. The stock has a market cap of $113.25 and a PE ratio of -1.94. The company has a quick ratio of 9.49, a current ratio of 9.49 and a debt-to-equity ratio of 0.17. aTyr Pharma has a 12 month low of $2.30 and a 12 month high of $6.50.

aTyr Pharma (NASDAQ:LIFE) last announced its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.43) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.50) by $0.07. sell-side analysts anticipate that aTyr Pharma will post -1.93 EPS for the current fiscal year.

Hedge funds have recently made changes to their positions in the stock. Artal Group S.A. purchased a new stake in shares of aTyr Pharma during the 3rd quarter valued at approximately $1,263,000. Victory Capital Management Inc. purchased a new stake in shares of aTyr Pharma during the 3rd quarter valued at approximately $455,000. Finally, Dimensional Fund Advisors LP increased its holdings in aTyr Pharma by 44.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 83,848 shares of the biotechnology company’s stock worth $423,000 after acquiring an additional 25,676 shares during the period. Institutional investors own 58.28% of the company’s stock.

WARNING: This piece of content was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3147709/atyr-pharma-life-rating-lowered-to-hold-at-zacks-investment-research.html.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get a free copy of the Zacks research report on aTyr Pharma (LIFE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.